INT251787

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 3.77
Pain Relevance 0.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

ESYT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 12 96.96 Very High Very High Very High
Potency 3 90.96 High High
antagonist 3 60.84 Quite High
Pain 6 40.20 Quite Low
Inflammation 15 5.00 Very Low Very Low Very Low
peripheral neuropathy 6 5.00 Very Low Very Low Very Low
tolerance 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Advanced Or Metastatic Breast Cancer 252 100.00 Very High Very High Very High
Cancer 105 100.00 Very High Very High Very High
Breast Cancer 177 99.72 Very High Very High Very High
Toxicity 42 97.20 Very High Very High Very High
Headache 12 96.96 Very High Very High Very High
Dizziness 3 96.44 Very High Very High Very High
Diarrhoea 42 96.00 Very High Very High Very High
Fatigue 30 95.60 Very High Very High Very High
Neuropathic Pain 6 92.96 High High
Alopecia 15 91.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It was concluded that the combination of tanespimycin and trastuzumab was active in HER2 positive MBC who progressed on trastuzumab based therapies with a relatively safe toxicity profile.
Positive_regulation (active) of MBC associated with toxicity and advanced or metastatic breast cancer
1) Confidence 0.05 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.60 Pain Relevance 0.10
Trastuzumab is combined with DM-1, a highly potent anti-microtubule agent derived from the fungal toxin maytansine.[12] At ASCO 2008, two phase I studies were presented for its use in HER2 positive advanced MBC.
Positive_regulation (advanced) of MBC associated with advanced or metastatic breast cancer
2) Confidence 0.05 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 0.98 Pain Relevance 0.05
With increasing tumor resistance to chemotherapy in MBC, it is of vital importance to continue to apply these novel therapies to current treatment standards and to continue to search for newer agents that are under investigation for use in breast cancer.
Positive_regulation (increasing) of MBC associated with cancer, breast cancer and advanced or metastatic breast cancer
3) Confidence 0.05 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.20 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox